MacroGenics, Inc.
NASDAQ:MGNXBiotechnology
+$0.08 today
- Market cap
- $125.90M
- Beta
- 1.20
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.11
Volume 0.72M
Average 0.98M
MGNX Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
MacroGenics, Inc.NASDAQ: MGNX
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $20.78M rose 57.5% year over year, ahead of the +3.1% change in trailing-twelve-month revenue. Sequentially, it fell 49.6% from the prior quarter. Over 3 fiscal years it compounded at -0.1% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $105.37M (-29.5%) for the fiscal year ending Dec 2026, a slowdown from the +0.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $20.78M-49.6% QoQ
- Last fiscal yearDec 2025
- $149.5M+0.8% YoY
- LTMMar 2026
- $157.08M+3.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +57.5% | +165.9% | +108.4 pp |
| 1 year | +0.8% | -29.5% | -30.3 pp |
| 3-year CAGR | -0.1% | -12.0% | -11.9 pp |
| 5-year CAGR | -4.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 149.5M USD
- Year-over-year change
- +0.8%
- 4-year CAGR
- +18.6%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 149.5M | +0.8% |
| FY2024 | 2024-12-31 | 148.34M | +159.4% |
| FY2023 | 2023-12-31 | 57.19M | -61.9% |
| FY2022 | 2022-12-31 | 150.02M | +98.3% |
| FY2021 | 2021-12-31 | 75.64M | — |
Revenue vs competitors
How MGNX compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +3.1% is the 3rd highest of 10, against a peer median of -78.3%.
- Over three fiscal years its annual growth of -0.1% compares with a peer median of -9.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $157.08M USD | +3.1% | -0.1% | |
| LTM Mar 2026 | $7.94M USD | +115.4% | — | |
| LTM Mar 2026 | $7.12M USD | +1199.6% | +69.0% | |
| LTM Mar 2026 | $1M USD | -78.3% | +15.3% | |
| LTM Mar 2026 | $134K USD | -61.7% | -24.9% | |
| FY2025 | $64K USD | -99.8% | — | |
| LTM Mar 2026 | €29.33K EUR | -77.4% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $0 USD | -100.0% | -22.3% |
| LTM Mar 2026 | $0 USD | -100.0% | — | |
| LTM Mar 2026 | $0 USD | -100.0% | -9.6% | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding MGNX) | — | -78.3% | -9.6% | |
Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75.64M | 150.02M | 57.19M | 148.34M | 149.5M |
| Cost of Revenue | 2.65M | 7.38M | 8.22M | 12.3M | 43.18M |
| Gross Profit | 72.99M | 142.63M | 48.97M | 136.04M | 106.32M |
| Gross Margin | 96.5% | 95.1% | 85.6% | 91.7% | 71.1% |
| Research & Development | 214.58M | 207.03M | 166.58M | 177.19M | 140M |
| Selling, General & Admin | 63.01M | 58.95M | 52.19M | 71.05M | 39.16M |
| Operating Expenses | 275.79M | 264.05M | 217.22M | 246.62M | 179.16M |
| Depreciation & Amortization | 11.26M | 11.87M | 9.65M | 7.54M | 7.17M |
| EBITDA | (190.86M) | (107.89M) | 2.02M | (57.37M) | (59.61M) |
| EBITDA Margin | -252.3% | -71.9% | 3.5% | -38.7% | -39.9% |
| Operating Income | (202.8M) | (121.42M) | (168.24M) | (110.58M) | (72.84M) |
| Operating Margin | -268.1% | -80.9% | -294.2% | -74.5% | -48.7% |
| Interest Income | 680K | 1.7M | 9.69M | 9.42M | 3.4M |
| Interest Expense | 0 | 0 | 1.43M | 1.12M | 8.51M |
| Other Income / Expenses | 680K | 1.66M | 159.19M | 44.56M | (2.45M) |
| Income Before Tax | (202.12M) | (119.76M) | (9.06M) | (66.02M) | (75.29M) |
| Pre-Tax Margin | -267.2% | -79.8% | -15.8% | -44.5% | -50.4% |
| Income Tax Expense | 0 | 0 | 0 | 944K | (672K) |
| Net Income | (202.12M) | (119.76M) | (9.06M) | (66.97M) | (74.62M) |
| Net Margin | -267.2% | -79.8% | -15.8% | -45.1% | -49.9% |
| EPS (Basic) | (3.18) | (1.95) | (0.15) | (1.07) | (1.18) |
| EPS (Diluted) | (3.18) | (1.95) | (0.15) | (1.07) | (1.18) |
| Weighted Avg Shares | 59.94M | 61.41M | 61.93M | 62.62M | 63.16M |
| Weighted Avg Shares (Diluted) | 59.94M | 61.43M | 61.93M | 62.62M | 63.16M |
MacroGenics, Inc.
NASDAQ:MGNX
Intrinsic Alpha fair value
Locked
Current Price
$1.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.